Last month we reported Gilead’s slashed pricing for ‘Sovaldi’ (its anti-Hepatitis C drug) in India as well as its proposals to tie up with Indian generics for the manufacture and export of the drug (see here and here). This week has seen the concretion of these deals with 7 Indian generic companies (see here and here). The Price Slash As the earlier posts outlined in detail, Gilead has been caught in widespread controversies across the world over its pricing for sofobuvir, brand...
↧